FMP
Vallon Pharmaceuticals, Inc.
VLON
NASDAQ
Inactive Equity
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
0.4 USD
-0.06 (-15%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. David C. Baker
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
CIK
0001824293
ISIN
US92023M1018
CUSIP
92023M101
Address
Two Logan Square
Phone
267 607 8255
Country
US
Employee
2
IPO Date
Feb 10, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
VLON Financial Summary
CIK
0001824293
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92023M101
ISIN
US92023M1018
Country
US
Price
0.4
Beta
-1.15
Volume Avg.
0
Market Cap
0
Shares
-
52-Week
0.3803-0.4308
DCF
0.18
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://www.vallon-pharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VLON News
It looks like there's no news available.
